Companies · ICLR
ICON Public Limited Company
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Aug 20, 2026
ICON Achieves Platinum ESG Status; Orbis AI Platform Gains Industry Recognition
ICON released its 2025 ESG report highlighting operational modernization through AI-enabled solutions and sustainability milestones. The company's proprietary Orbis platform won AI Project of the Year at the Analytics & AI Awards 2025, signaling deepening AI deployment across clinical trial operations. In 2025, ICON supported 1,370 clinical studies involving 411,400 patients, contributing to 25 unique product approvals, while achieving Platinum Medal status on EcoVadis (87/100) and ranking in the top 1% of assessed organizations globally.
Tone: bullishRevenue
$8.3B
ICLR 20-F · FY 2025
Employees
40,100
Revenue growth YoY
+0.8%
Founded
1990
Profile
ICLR 20-F Item 4.B · May 27, 2026ICON plc is a global contract research organization (CRO) founded in Dublin, Ireland in 1990 that provides outsourced clinical development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations. The company offers services spanning all phases of clinical development (Phases I-IV), laboratory testing, data solutions, and site and patient access. ICON operates in 55 countries and believes it is the world's largest pure-play CRO.
Read filing description ↓ Collapse description ↑
ICON is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations. We offer a full range of clinical, consulting and commercial services that range from clinical development strategy, planning and trial design, to full study execution, and post-market commercialization. ICON provides its services across a range of clinical outsourcing operating models including strategic partnerships, preferred provider, full-service delivery to functional service provision and stand-alone services. We specialize in the strategic development, management and analysis of programs that support all stages of the clinical development process, from compound selection to Phase I-IV clinical studies. We earn revenue by providing a number of different services to our customers. These services are integral components of the clinical development process and include clinical trial management, consulting, contract staffing, data solutions and laboratory services. Our vision is to be the partner of choice by delivering industry leading solutions and best in class performance in clinical development. We believe that we are one of a select group of CROs with the expertise and capability to conduct clinical trials in the major therapeutic areas on a global basis and have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated full-service solution. In order to achieve this vision, we continue to invest in technology and data analytics capabilities. ICON maintains a sustained focus on research and development. We continue to enhance our portfolio of data solutions and decentralized clinical trial technology through the development of industry-leading technologies and processes to support our clients. ICON is leading the industry transformation through four key levers: transforming clinical trials, site and patient centricity, applied innovation, and seamless, integrated service delivery.
Primary products
- clinical trial management
- consulting
- contract staffing
- data solutions
- laboratory services
- bio-analytical services
End markets
Geographies
Named customers
During the year ended December 31, 2025, revenue was earned from a wide range of customers and 24.8% of our revenues were derived from our top five customers, with no one customer individually contributing more than 10% of our revenues during the period. Our largest customer represented a strategic partnership with a large global pharmaceutical company and contributed 7.0% of revenue for the year.
Named competitors
“We believe that we are one of a select group of CROs with the expertise and capability to conduct clinical trials in the major therapeutic areas on a global basis and have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated full-service solution.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Revenue for the year ended December 31, 2025 increased by $62.4 million, or 0.8%, to $8,251.3 million, compared to $8,189.0 million (as restated) for the year ended December 31, 2024; reported in USD.
The rest of ICLR is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.